182 related articles for article (PubMed ID: 33213899)
1. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Boerner T; Tanner E; Filippova O; Zhou QC; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Gardner GJ; Sonoda Y; Abu-Rustum NR; Zivanovic O; Long Roche K; Afonso AM; Fischer M; Chi DS
Gynecol Oncol; 2021 Jan; 160(1):51-55. PubMed ID: 33213899
[TBL] [Abstract][Full Text] [Related]
2. A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
Tanner EJ; Filippova OT; Gardner GJ; Long Roche KC; Sonoda Y; Zivanovic O; Fischer M; Chi DS
Gynecol Oncol; 2018 Dec; 151(3):433-437. PubMed ID: 30336947
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
4. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
5. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection.
Jarnagin WR; Gonen M; Maithel SK; Fong Y; D'Angelica MI; Dematteo RP; Grant F; Wuest D; Kundu K; Blumgart LH; Fischer M
Ann Surg; 2008 Sep; 248(3):360-9. PubMed ID: 18791356
[TBL] [Abstract][Full Text] [Related]
7. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
8. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
9. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
10. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
[TBL] [Abstract][Full Text] [Related]
11. Mild volume acute normovolemic hemodilution is associated with lower intraoperative transfusion and postoperative pulmonary infection in patients undergoing cardiac surgery -- a retrospective, propensity matching study.
Zhou ZF; Jia XP; Sun K; Zhang FJ; Yu LN; Xing T; Yan M
BMC Anesthesiol; 2017 Jan; 17(1):13. PubMed ID: 28122491
[TBL] [Abstract][Full Text] [Related]
12. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
Wallace S; Kumar A; Mc Gree M; Weaver A; Mariani A; Langstraat C; Dowdy S; Bakkum-Gamez J; Cliby W
Gynecol Oncol; 2017 Apr; 145(1):21-26. PubMed ID: 28159407
[TBL] [Abstract][Full Text] [Related]
13. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
[TBL] [Abstract][Full Text] [Related]
14. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Boerner T; Filippova OT; Chi AJ; Iasonos A; Zhou QC; Long Roche K; Zivanovic O; Park BJ; Huang J; Jones DR; Abu-Rustum NR; Gardner G; Sonoda Y; Chi DS
Gynecol Oncol; 2020 Oct; 159(1):66-71. PubMed ID: 32792282
[TBL] [Abstract][Full Text] [Related]
15. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute normovolemic hemodilution and allogeneic blood transfusion on postoperative complications of oral and maxillofacial flap reconstruction: a retrospective study.
Li W; Li X; Chen Y; Li Y; Chen R; Kang Z; Huang Z; Zhao Y
BMC Oral Health; 2024 May; 24(1):606. PubMed ID: 38789959
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
18. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088
[TBL] [Abstract][Full Text] [Related]
19. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
[TBL] [Abstract][Full Text] [Related]
20. Low-Volume Acute Normovolemic Hemodilution Does Not Reduce Allogeneic Red Blood Cell Transfusion in Cardiac Surgery in the Modern Era of Patient Blood Management: A Propensity Score-Matched Cohort Study.
Yoshinaga K; Iizuka Y; Sanui M; Faraday N
J Cardiothorac Vasc Anesth; 2024 Feb; 38(2):394-402. PubMed ID: 38052691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
